HJHamidreza Jamalabadi

Hamidreza Jamalabadi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hamidreza Jamalabadi has a total of 781 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A reproducible structural brain axis of alcohol use severity

    by Julius Wiegert, Jailan Oweda, Esra Lenz, Sebastian Volkmer, Xiuzhi Li, Amrou Abas, Antonia Mai, Lilli Roetzer, Susanne Meinert, Elisabeth J. Leehr, et al.

    Alcohol use is linked to distributed structural brain alterations, but population-level alcohol-related neurobiology remains difficult to quantify. We tested whether deep learning–derived MRI representations capture reproducible variation in alcohol consumption severity and converge with clinical and biological markers. Representations were extracted from gray-matter volume maps in the German National Cohort (NAKO; N ≈ 28,000). Ridge-regression scores were derived from structural MRI to estimate alcohol consumption severity, measured with the Alcohol Use Disorders Identification Test–Consumption (AUDIT-C). Models were trained in NAKO, externally validated in UK Biobank ( N ≈ 25,000), evaluated in FOR2107 ( N ≈ 1900), and tested against ICD-10 alcohol use disorder (AUD), alcohol-related biomarkers, and cognition. In NAKO, the structural MRI-derived ridge-regression score correlated with measured AUDIT-C severity ( r = 0.11; 95% CI, 0.09–0.12; q FDR = 1.2 × 10 −70 ; MAE = 1.64). This association replicated in UK Biobank ( r = 0.09; 95% CI, 0.07–0.10; q FDR = 4.9 × 10 −41 ; MAE = 1.96) and generalized to AUD, with higher odds in the highest versus lowest brain-score quintile (OR = 2.28; 95% CI, 1.49–3.48; q FDR = 3.9 × 10 −4 ). The score was associated with gamma-glutamyl transferase ( β = 1.17 U/L; q FDR = 0.007), mean corpuscular volume ( β = 14.26 fL; q FDR = 4.4 × 10 −4 ), and slower reaction time ( β = 163.40 ms; q FDR = 3.0 × 10 −5 ). Deep learning–derived structural MRI representations capture weak but reproducible alcohol-related brain variation that converges with AUD diagnosis, peripheral biomarkers, and cognition, supporting their use in population-level addiction neuroscience while underscoring limits for individual-level prediction.

  • Open Access

    Distinct profiles of white matter diffusivity in obesity and bipolar disorders: An ENIGMA bipolar disorders study in 2166 individuals

    by Lorielle M. F. Dietze, Sean R. McWhinney, Pauline Favre, Christoph Abé, Martin Alda, Nina Alexander, Jochen Bauer, Francesco Benedetti, Michael Berk, Erlend Bøen, et al.

    Background: Bipolar disorders (BD) are associated with a wide range of brain white matter abnormalities, but results vary across studies. This heterogeneity likely relates to effects of additional clinical/diagnostic variables, including medications and obesity, on white matter in BD. In this mega-analysis, we studied the links between relevant clinical variables and four diffusivity measures. Methods: We obtained diffusion tensor imaging-derived fractional anisotropy (FA), mean, axial, and radial diffusivity (MD, AD, RD) values from 910 individuals with BD and 1256 healthy controls across 16 research sites in the ENIGMA-BD Working Group. We used principal component analysis to detect patterns of covariance across white matter tracts and studied associations between multivariate patterns of white matter alterations and demographic and clinical variables, including body mass index (BMI), medications, and diagnostic information, using mixed regression models. Results: Higher BMI was associated with lower PC1 FA and higher PC1 RD; BD was associated with higher PC1 MD, while treatment with antiepileptic medications was associated with lower PC1 FA, higher PC1 MD, and PC1 RD. Conclusions: We found FA and MD are weakly associated, providing complementary information, and there are unique associations between specific diffusivity measures and clinical predictors. Treatment with antiepileptics may inflate the statistical effects of BD on white matter. By using all diffusivity measures and accounting for additional clinical factors, we can gain new insights into brain correlates of severe mental illness.

  • Open Access

    Connectome-wide dysconnectivity signature tracks clinical status in major depressive disorder

    by Marius Gruber, Ilan Libedinsky, Kira F. Ahrens, Paula Rehm, Henry Staub, Stefanie Fischer, Franka Timm, Sharmili Edwin Thanarajah, Kira Flinkenflügel, Tiana Borgers, et al.

    Major depressive disorder (MDD) is increasingly conceptualized as a dysconnection syndrome involving widespread brain network disruptions. However, most neuroimaging studies rely on within-sample case–control comparisons, leaving unclear whether identified connectivity patterns generalize across populations or explain clinical variation within patients. In this cross-sectional observational study, we test whether a depression-related connectivity pattern from a Japanese cohort (824 controls, 229 MDD) generalizes to a German cohort (923 controls, 694 MDD) using polyconnectomic scores (PCS), a metric for quantifying whole-brain connectivity disturbances. PCS MDD significantly distinguished patients from controls ( z = 5.1, P < 0.001), with the highest scores in acutely depressed patients. Its diagnostic signal was distributed across the connectome, with performance declining under stricter edge-level thresholds. PCS MDD captured a spatially specific dysconnectivity pattern that explained variance beyond mean within- and between-network connectivity summaries. No associations were found between PCS MDD and past disease course in MDD patients. By contrast, patients with higher PCS MDD exhibited greater current symptom severity ( r = 0.09, P = 0.022), particularly loss of pleasure ( r = 0.12, P FDR = 0.041). These findings demonstrate that a depression-related connectivity pattern generalizes across populations and relates selectively to current symptom severity.

  • Open Access

    Insomnia and anxiety exhibit distinct short-term associations following ketamine in treatment-resistant depression

    by Nadia S. Hejazi, Mina Kheirkhah, Robin Chholak, Brady Riedner, Hamidreza Jamalabadi, Martin Walter, Stefan G. Hofmann, Wallace Duncan, David Goldman, Carlos A. Zarate

    Insomnia and anxiety frequently co-occur with treatment-resistant depression (TRD). This study examined short-term changes in depression, anxiety, and insomnia symptoms post-ketamine in TRD and their inter-relationships. Seventy-one patients with TRD were assessed at baseline and 24 h after intravenous ketamine (0.5 mg/kg). Depression, anxiety, and insomnia were measured using the Montgomery–Åsberg Depression Rating Scale (MADRS), the Hamilton Anxiety Rating Scale (HAM-A), and insomnia items from the Hamilton Depression Rating Scale (HAM-D), respectively. Linear mixed-effects models tested pre–post changes, while Spearman, Pearson, and simple linear regression examined associations between symptom domains. As an exploratory analysis, linear discriminant analysis (LDA) and logistic regression were used to classify insomnia improvement. All symptom domains decreased significantly post-ketamine treatment, including depression (MADRS; β = –11.72, P < 0.001), anxiety (HAM-A; β = –7.87, P < 0.001), and insomnia ( β = –0.89, P < 0.001). At baseline, insomnia was moderately correlated with anxiety (Spearman ρ = 0.36), and anxiety was correlated with depression (Pearson r = 0.39); similar associations were observed post-ketamine (Spearman ρ = 0.36; Pearson r = 0.57). Changes in anxiety were strongly associated with changes in depression (Spearman ρ = 0.61), whereas changes in insomnia were not significantly associated with changes in either domain. Greater baseline insomnia severity was associated with larger absolute insomnia reductions. Exploratory polysomnography analyses suggested short-term increases in total sleep time, slow-wave sleep, and sleep efficiency, and reduced sleep latency. In conclusion, although all symptom domains decreased post-ketamine, short-term changes in HAM-D insomnia symptoms were not significantly associated with changes in depression or anxiety in TRD. Clinical Trial Identifier : www.clinicaltrials.gov (NCT00088699)

  • The metabolic regulator: Why energy constraints imply generative models

    by Hamidreza Jamalabadi, Tim Hahn

    We argue that under minimal thermodynamic and control-theoretic assumptions, metabolic constraints imply generative cognition. We formalize cognition as a resource-bounded controller of probability flows, where metabolic budgets define path-space divergence constraints. This reframes inference as a physically instantiated process governed by metabolic regulation, implying that progress in the cognitive sciences requires grounding cognitive models in nonequilibrium thermodynamics and dynamical systems.

  • Open Access

    Resilience beyond diagnosis: prospective neural correlates of better-than-expected outcomes in depression

    by Vincent Hammes, Katharina Brosch, Paula Usemann, Friederike S. David, Hannah Scherer, Christina Schmitter, Jochen Bauer, Tiana Borgers, Kira Flinkenflügel, Dominik Grotegerd, et al.

    Resilience, the ability to adapt positively in the face of adversity, is shaped by combined influences of risk and protective factors. Previous neuroimaging studies on resilience have predominantly focused on single factors, often operationalizing resilience dichotomously as the absence of psychiatric disorders despite adversity. In this prospective magnetic resonance imaging study, we defined resilience as “better-than-expected” depressive symptom severity (Hamilton Depression Rating Scale) relative to cumulative risk across 22 risk and protective variables. Using ridge-regularized regression in N = 1804 participants (955 healthy, 849 depressed) from the Marburg-Münster Affective Disorders Cohort Study, we predicted symptom severity and derived residuals as measures of resilience. Residuals were then used to predict gray matter volume (GMV) and cortical thickness at baseline (T1) and two-year follow-up (T2; N = 808). This approach was complemented by extreme-group comparisons of resilient (better-than-expected outcome) and vulnerable (worse-than-expected outcome) individuals. Cumulative risk explained 49.6% of variance in depressive symptoms at T1 and 40.1% at T2. Residual scores showed moderate temporal stability ( r = 0.32, p < 0.001). Region-of-interest and whole-brain analyses revealed no morphometric associations with resilience at T1. In contrast, higher resilience at T1 predicted lower GMV in the left inferior orbitofrontal gyrus (IOFG) and temporal pole at T2 (ROI, p FWE(peak) r partial = 0.18), with no changes in cortical thickness. Taken together, resilience to cumulative risk, defined as better-than-expected depressive symptom severity, was not associated with immediate brain structural differences. However, prospective analyses revealed smaller GMV in the IOFG and temporal pole over time, potentially reflecting greater neural efficiency or delayed biological costs.

  • Open Access

    When Being Social Is Costly: Empathy's Role for Risk States, Acute Symptoms, and Cumulative Disease Severity of Depression

    by Dahna Choi, Paula L. Usemann, Katharina Förster, Roland Zahn, Vincent Hammes, Frederike Stein, Florian Thomas‐Odenthal, Lea Teutenberg, Kira Flinkenflügel, Julia Hubbert, et al.

    Objectives: Patients with major depressive disorder (MDD) frequently report burdensome interpersonal difficulties and altered empathy and perspective‐taking. Previous findings on binary comparisons between patients and healthy controls are limited in their clinical translation as they neglect dissociable risk and disease states. In this preregistered study ( https://osf.io/k6mdh/overview?view_only=04b7f39f59a8434292cd472120f661ca ), we extend case‐control comparisons by additionally investigating empathic distress, empathic concern, and perspective‐taking in association with (a) familial MDD risk, (b) acute symptom severity, and (c) cumulative MDD severity. Method: We analyzed data from n = 499 MDD patients and n = 670 healthy controls from the Marburg‐Münster‐Affective‐Cohort Study. Robust linear regressions were run to investigate group differences in self‐reported empathy and perspective‐taking and their associations with acute symptom severity and familial MDD risk. Analyses on cumulative MDD severity were run in a structural equation model. Results: Empathic distress was positively associated with both acute and cumulative MDD severity and was elevated in patients compared to healthy controls. A positive association between empathic distress and familial MDD risk became non‐significant after adjustment for age and sex. Patients also reported higher levels of empathic concern—likely influenced by acute symptom severity—and slightly lower levels of perspective‐taking. Conclusions: Our associational findings indicate empathic distress to constitute a correlate of acute MDD and longer‐term MDD progression, while its relevance for MDD risk requires further investigation. We provide new indications of a generalized heightened emotional attunement during acute depression, entailing both empathic concern and empathic distress. Longitudinal studies are warranted to probe causal associations to prospectively inform psychotherapeutic interventions addressing maladaptive empathic processes.

  • Open Access

    Secure Attachment despite Childhood Maltreatment: Behavioral and Neural Correlates of Interpersonal Resilience

    by Katharina Brosch, Vincent Hammes, Paula Usemann, Frederike Stein, Sunny X. Tang, Rebecca M. Schwartz, Florian Thomas-Odenthal, Lea Teutenberg, Nooshin Javaheripour, Susanne Meinert, et al.

    Background: Childhood maltreatment is a traumatic interpersonal stressor that increases vulnerability for depression in adulthood. However, some individuals show secure attachment despite childhood maltreatment, a pattern that can be described as interpersonal resilience. The present study examined the behavioral and neural correlates of interpersonal resilience, defined as secure attachment in adults exposed to childhood maltreatment. Methods: We analyzed structural 3T MRI data from 1,317 adults, including healthy participants and individuals with partially or fully remitted major depression. Gray matter volume was estimated from structural MRI data using voxel-based morphometry. Attachment style and childhood maltreatment were assessed using the Relationship Scales Questionnaire and the Childhood Trauma Questionnaire, respectively. A 2×2 design (childhood maltreatment by attachment style) tested main and interaction effects on behavioral outcomes and brain structure. Results: Interpersonally resilient individuals with secure attachment and maltreatment reported significantly better mental health outcomes compared to insecurely attached adults with maltreatment. Differences included lower self-reported and rater-based depressive symptoms, lower global symptom severity, and higher global functioning. In the neuroimaging analyses, we identified a significant childhood maltreatment by attachment style interaction in the left supramarginal gyrus, with larger gray matter volume in resilient individuals compared to all other groups. This effect remained robust across multiple sensitivity analyses, controlling for medication load, antidepressant intake, diagnosis group, as well as in a complementary dimensional analysis. Conclusions: The results identify a potential neural correlate of interpersonal resilience. Larger gray matter volume in the left supramarginal gyrus, a region previously implicated in perspective taking and self-other distinction among other functions, may be relevant to more adaptive interpersonal functioning after early adversity. Together with the robust behavioral effects, these findings are consistent with secure attachment as a protective factor that may be associated with attenuated effects of childhood maltreatment on mental health.

  • Open Access

    The effect of SSRI/SNRI antidepressant treatment on the gut microbiota of patients with major depressive disorder

    by Eugenia Emile Natasha, Danique Mulder, Leon Fehse, Nils R. Winter, Lukas Fisch, Marius Welzel, Corinna Bang, Susanne Meinert, Kira Flinkenflügel, Tiana Borgers, et al.

    Background: The gut microbiome has been linked to major depressive disorder (MDD), yet it remains unclear whether antidepressant treatment influences these associations. This study aimed to clarify the role of serotonin reuptake inhibitors (SSRI/SNRI) in shaping gut microbiome changes observed in MDD. Methods: We conducted cross-sectional analyses in two independent patient cohorts (total N = 1802) and a meta-analysis across both cohorts, comparing the gut microbiome of MDD patients with and without SSRI/SNRI treatment. Results: Here we show that SSRI/SNRI treatment is consistently associated with reduced Clostridium sensu stricto 1 abundance. This effect is specific to SSRI/SNRI treatment and not observed with other psychotropic medications. Importantly, reductions in Clostridium sensu stricto 1 in MDD compared to unaffected controls are explained by SSRI/SNRI medication status. Conclusions: Antidepressant treatment is an important factor shaping gut microbiome alterations linked to MDD, underscoring the need to account for medication effects and potentially informing future microbiome-based strategies to improve treatment response.

  • Open Access

    Resilience Beyond Diagnosis: Prospective Neural Correlates of Better-Than-Expected Outcomes in Depression

    by Vincent Hammes, Katharina Brosch, Paula Usemann, Friederike David, Hannah Scherer, Christina Schmitter, Jochen Bauer, Tiana Borgers, Kira Flinkenflügel, Dominik Grotegerd, et al.

    Resilience, the ability to adapt positively in the face of adversity, is shaped by combined influences of risk and protective factors. Previous neuroimaging studies on resilience have predominantly focused on single factors, often operationalizing resilience dichotomously as the absence of psychiatric disorders despite adversity. In this prospective magnetic resonance imaging study, we defined resilience as “better-than-expected” depressive symptom severity (Hamilton Depression Rating Scale) relative to cumulative risk across 22 risk and protective variables. Using ridge-regularized regression in N = 1804 participants (955 healthy, 849 depressed) from the Marburg-Münster Affective Disorders Cohort Study, we predicted symptom severity and derived residuals as measures of resilience. Residuals were then used to predict gray matter volume (GMV) and cortical thickness at baseline (T1) and two-year follow-up (T2; N = 808). This approach was complemented by extreme-group comparisons of resilient (better-than-expected outcome) and vulnerable (worse-than-expected outcome) individuals. Cumulative risk explained 49.6% of variance in depressive symptoms at T1 and 40.1% at T2. Residual scores showed moderate temporal stability ( r = 0.32, p < 0.001). Region-of-interest and whole-brain analyses revealed no morphometric associations with resilience at T1. In contrast, higher resilience at T1 predicted lower GMV in the left inferior orbitofrontal gyrus (IOFG) and temporal pole at T2 (ROI, p FWE(peak) < 0.001, r partial =0.18), with no changes in cortical thickness. Taken together, resilience to cumulative risk, defined as better-than-expected depressive symptom severity, was not associated with immediate brain structural differences. However, prospective analyses revealed smaller GMV in the IOFG and temporal pole over time, potentially reflecting greater neural efficiency or delayed biological costs.